Join
Live feed
·
PRReleasevia Quantisnow
Design Therapeutics Inc. logo

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

ByQuantisnow·Wall Street's wire, on your screen.
DSGN· Design Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DSGN (Design Therapeutics Inc.) and more on Quantisnow.